@article{TAU20173,
author = {Stéphane Culine and Yves Allory and Christian Pfister},
title = {Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization},
journal = {Translational Andrology and Urology},
volume = {7},
number = {4},
year = {2018},
keywords = {},
abstract = {Radical cystectomy (RC) remains the standard of care as local treatment of muscle-invasive bladder cancer (MIBC). However, the cancer-specific survival is approximately 50%, depending on the presence of extravesical extension and lymph node metastases. In other words, nearly 50% of patients develop metastases within 2 years after RC, implying the presence of micro-metastases at the time of surgery. Neoadjuvant chemotherapy (NAC) has been shown to improve survival of patients and international guidelines recommend NAC based on the available level I evidence (1,2).},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/20173}
}